293 related articles for article (PubMed ID: 25188473)
21. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
23. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N
Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():12-21. PubMed ID: 30288929
[TBL] [Abstract][Full Text] [Related]
24. The Role of CDK4/6 Inhibitors in Breast Cancer.
Murphy CG
Curr Treat Options Oncol; 2019 May; 20(6):52. PubMed ID: 31101994
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
26. Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.
Bayraktar S; Batoo S; Al-Hattab E; Basu S; Okuno S; Glück S
Future Oncol; 2020 Nov; 16(32):2661-2672. PubMed ID: 32805138
[TBL] [Abstract][Full Text] [Related]
27. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
Pandey K; An HJ; Kim SK; Lee SA; Kim S; Lim SM; Kim GM; Sohn J; Moon YW
Int J Cancer; 2019 Sep; 145(5):1179-1188. PubMed ID: 30478914
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
30. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
31. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
Hui R; de Boer R; Lim E; Yeo B; Lynch J
Asia Pac J Clin Oncol; 2021 Jan; 17 Suppl 1():3-14. PubMed ID: 33506626
[TBL] [Abstract][Full Text] [Related]
35. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.
Xu XQ; Pan XH; Wang TT; Wang J; Yang B; He QJ; Ding L
Acta Pharmacol Sin; 2021 Feb; 42(2):171-178. PubMed ID: 32504067
[TBL] [Abstract][Full Text] [Related]
37. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
38. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
39. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Rossi L; McCartney A; Risi E; De Santo I; Migliaccio I; Malorni L; Biganzoli L; Di Leo A
Clin Breast Cancer; 2019 Dec; 19(6):392-398. PubMed ID: 31358432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]